Comparing the Efficacy of 75mg Versus 150mg Aspirin for the Prevention of Preeclampsia in High-Risk Pregnant Women

ConditionPreeclampsia (PE)

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexFemale

Age18-30

SponsorShalamar Hospital

About this trial

This study aims to evaluate the effectiveness of 75 mg aspirin versus 150 mg aspirin in preventing preeclampsia among individuals with high risk for the condition. Existing literature suggests that the 150 mg aspirin dose may exhibit superior efficacy, yet inconclusive evidence exists in our local setting.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Screen positive women

Age 18 - 30 y

Gestational Age 11 - 13+6 weeks

Singleton Pregnancy

Disqualifiers

Screen negative women

Age > 30 y

Gestational Age > 14 weeks

Multiple Gestation

Trial design

Design model

Parallel

Treatments tested in this trial

Aspirin 75 mg
Drug
This study aims to evaluate the effectiveness of 75 mg aspirin versus 150 mg aspirin in preventing preeclampsia among individuals with high risk for the condition. Eligible women attending the antenatal clinic were screened by history, physical exam, and uterine artery Doppler. Risk assessment was entered into the Fetal Medicine Foundation software. Participants were randomized: Group A: 75 mg aspirin nightly. Group B: 150 mg aspirin nightly.
Aspirin 150 mg
Drug
This study aims to evaluate the effectiveness of 75 mg aspirin versus 150 mg aspirin in preventing preeclampsia among individuals with high risk for the condition. Eligible women attending the antenatal clinic were screened by history, physical exam, and uterine artery Doppler. Risk assessment was entered into the Fetal Medicine Foundation software. Participants were randomized: Group A: 75 mg aspirin nightly. Group B: 150 mg aspirin nightly.

Treatment groups

340 Participants

are divided into 2 treatment groups

Group A: Group AExperimental treatment 1 intervention

Group B: Group BExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

Pre - eclampsia

PE (Pre-eclampsia) Yes / No Early Onset - Pre-eclampsia (\<34 weeks) Yes / No Late Onset - Pre-eclampsia (\>34 weeks) Yes / No

Time frame

9 months

Secondary outcomes

Delivery

Preterm - Pre-eclampsia Delivery (\<37 weeks) Yes / No Term Delivery - Pre-eclampsia (\>37 weeks) Yes / No

Time frame

9 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Shalamar Hospital

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: